Sachin M. Apte, MD, MS

BOARD CERTIFICATION:
          •  Obstetrics & Gynecology - Gynecologic Oncology

FELLOWSHIP:
          •  The University of Texas M. D. Anderson Cancer Center

RESIDENCY:
          •  The Ohio State University Hospitals

MEDICAL SCHOOL:
          •  The Ohio State University College of Medicine - MD

• Marchion DC, Bicaku E, Xiong Y, Zgheib NB, Al Sawah E, Stickles XB, Judson PL, Lopez AS, Cubitt CL, Gonzalez-Bosquet J, Wenham RM, Apte SM, Berglund A, Lancaster JM. A novel c-Met inhibitor, MK8033, synergizes with carboplatin plus paclitaxel to inhibit ovarian cancer cell growth. Oncol Rep. 2013 May;29(5):2011-2018. Pubmedid: 23467907.


• Wenham RM, Lapolla J, Lin HY, Apte SM, Lancaster JM, Judson PL, Gonzalez-Bosquet J, Herschberger A, Havrilesky LJ, Secord AA. A phase II trial of docetaxel and bevacizumab in recurrent ovarian cancer within 12 months of prior platinum-based chemotherapy. Gynecol Oncol. 2013 Apr. Pubmedid: 23623830.


• Koh WJ, Greer BE, Abu-Rustum NR, Apte SM, Campos SM, Chan J, Cho KR, Cohn D, Crispens MA, Dupont N, Eifel PJ, Gaffney DK, Giuntoli RL, Han E, Huh WK, Lurain JR, Martin L, Morgan MA, Mutch D, Remmenga SW, Reynolds RK, Small W, Teng N, Tillmanns T, Valea FA, McMillian NR, Hughes M. Cervical cancer. J Natl Compr Canc Netw. 2013 Mar;11(3):320-343. Pubmedid: 23486458.


• Teefey P, Zgheib NB, Apte SM, Gonzalez-Bosquet J, Judson PL, Roberts WS, Lancaster JM, Wenham RM. Factors associated with improved toxicity and tolerability of intraperitoneal chemotherapy in advanced-stage epithelial ovarian cancers. Am J Obstet Gynecol. 2013 Mar. Pubmedid: 23507546.


• Phillips KM, Faul LA, Small BJ, Jacobsen PB, Apte SM, Jim HS. Comparing the Retrospective Reports of Fatigue Using the Fatigue Symptom Index With Daily Diary Ratings in Women Receiving Chemotherapy for Gynecologic Cancer. J Pain Symptom Manage. 2012 Nov. Pubmedid: 23159686.


• Judson PL, Al Sawah E, Marchion DC, Xiong Y, Bicaku E, Zgheib NB, Chon HS, Stickles XB, Hakam A, Wenham RM, Apte SM, Gonzalez-Bosquet J, Chen DT, Lancaster JM. Characterizing the efficacy of fermented wheat germ extract against ovarian cancer and defining the genomic basis of its activity. Int J Gynecol Cancer. 2012 Jul;22(6):960-967. Pubmedid: 22740002.


• Zgheib NB, Xiong Y, Marchion DC, Bicaku E, Chon HS, Stickles XB, Sawah EA, Judson PL, Hakam A, Gonzalez-Bosquet J, Wenham RM, Apte SM, Cubitt CL, Chen DT, Lancaster JM. The O-glycan pathway is associated with in vitro sensitivity to gemcitabine and overall survival from ovarian cancer. Int J Oncol. 2012 Jul;41(1):179-188. Pubmedid: 22552627.


• Bicaku E, Xiong Y, Marchion DC, Chon HS, Stickles XB, Chen N, Judson PL, Hakam A, Gonzalez-Bosquet J, Wenham RM, Apte SM, Fulp W, Cubitt CL, Chen DT, Lancaster JM. In vitro analysis of ovarian cancer response to cisplatin, carboplatin, and paclitaxel identifies common pathways that are also associated with overall patient survival. Br J Cancer. 2012 Jun;106(12):1967-1975. Pubmedid: 22596241. Pmcid: PMC3388569.


• Chon HS, Marchion DC, Xiong Y, Chen N, Bicaku E, Stickles XB, Zgheib NB, Judson PL, Hakam A, Gonzalez-Bosquet J, Wenham RM, Apte SM, Lancaster JM. The BCL2 antagonist of cell death pathway influences endometrial cancer cell sensitivity to cisplatin. Gynecol Oncol. 2012 Jan;124(1):119-124. Pubmedid: 22032837.


• Bansal N, Marchion DC, Bicaku E, Xiong Y, Chen N, Stickles XB, Sawah EA, Wenham RM, Apte SM, Gonzalez-Bosquet J, Judson PL, Hakam A, Lancaster JM. BCL2 antagonist of cell death kinases, phosphatases, and ovarian cancer sensitivity to cisplatin. J Gynecol Oncol. 2012 Jan;23(1):35-42. Pubmedid: 22355465.


• Jim HS, Small B, Faul LA, Franzen J, Apte S, Jacobsen PB. Fatigue, depression, sleep, and activity during chemotherapy: daily and intraday variation and relationships among symptom changes. Ann Behav Med. 2011 Dec;42(3):321-333. Pubmedid: 21785899. Pmcid: PMC3432914.


• Marchion DC, Cottrill HM, Xiong Y, Chen N, Bicaku E, Fulp WJ, Bansal N, Chon HS, Stickles XB, Kamath SG, Hakam A, Li L, Su D, Moreno C, Judson PL, Berchuck A, Wenham RM, Apte SM, Gonzalez-Bosquet J, Bloom GC, Eschrich SA, Sebti S, Chen DT, Lancaster JM. BAD phosphorylation determines ovarian cancer chemosensitivity and patient survival. Clin Cancer Res. 2011 Oct;17(19):6356-6366. Pubmedid: 21849418. Pmcid: PMC3186862.


• Ramirez I, Chon HS, Apte SM. The role of surgery in the management of epithelial ovarian cancer. Cancer Control. 2011 Jan;18(1):22-30. Pubmedid: 21273977.


• Greer BE, Koh WJ, Abu-Rustum NR, Apte SM, Campos SM, Chan J, Cho KR, Copeland L, Crispens MA, Dupont N, Eifel PJ, Gaffney DK, Huh WK, Kapp DS, Lurain JR, Martin L, Morgan MA, Morgan RJ, Mutch D, Remmenga SW, Reynolds RK, Small W, Teng N, Valea FA. Cervical cancer. J Natl Compr Canc Netw. 2010 Dec;8(12):1388-1416. Pubmedid: 21147903.


• Indermaur MD, Xiong Y, Kamath SG, Boren T, Hakam A, Wenham RM, Apte SM, Lancaster JM. Genomic-directed targeted therapy increases endometrial cancer cell sensitivity to doxorubicin. Am J Obstet Gynecol. 2010 Aug;203(2):158.e1-158.40. Pubmedid: 20444440.


• Kamath SG, Chen N, Xiong Y, Wenham R, Apte S, Humphrey M, Cragun J, Lancaster JM. Gedunin, a novel natural substance, inhibits ovarian cancer cell proliferation. Int J Gynecol Cancer. 2009 Dec;19(9):1564-1569. Pubmedid: 19955938.


• Bansal N, Roberts WS, Apte SM, Lancaster JM, Wenham RM. Electrothermal bipolar coagulation decreases the rate of red blood cell transfusions for pelvic exenterations. J Surg Oncol. 2009 Nov;100(6):511-514. Pubmedid: 19697350.


• Hoffman MS, Ondrovic LE, Wenham RM, Apte SM, Shames ML, Zervos EE, Weinberg WS, Roberts WS. Evaluation of the porcine model to teach various ancillary procedures to gynecologic oncology fellows. Am J Obstet Gynecol. 2009 Jul;201(1):116.e1-116.e3. Pubmedid: 19576378.


• Boren T, Xiong Y, Hakam A, Wenham R, Apte S, Chan G, Kamath SG, Chen DT, Dressman H, Lancaster JM. MicroRNAs and their target messenger RNAs associated with ovarian cancer response to chemotherapy. Gynecol Oncol. 2009 May;113(2):249-233. Pubmedid: 19237188.


• Schmeler KM, Vadhan-Raj S, Ramirez PT, Apte SM, Cohen L, Bassett RL, Iyer RB, Wolf JK, Levenback CL, Gershenson DM, Freedman RS. A phase II study of GM-CSF and rIFN-gamma1b plus carboplatin for the treatment of recurrent, platinum-sensitive ovarian, fallopian tube and primary peritoneal cancer. Gynecol Oncol. 2009 May;113(2):210-215. Pubmedid: 19264351.


• Humphrey MM, Apte SM. The use of minimally invasive surgery for endometrial cancer. Cancer Control. 2009 Jan;16(1):30-37. Pubmedid: 19078927.


• Boren T, Xiong Y, Hakam A, Wenham R, Apte S, Wei Z, Kamath S, Chen D, Dressman H, Lancaster J. MicroRNAs and their target messenger RNAs associated with endometrial carcinogenesis. Gynecol Oncol. 2008 Aug;110(2):206-215. Pubmedid: 18499237.


• Apte SM, Vadhan-Raj S, Cohen L, Bassett RL, Gordon IO, Levenback CF, Ramirez PT, Gallardo ST, Patenia RS, Garcia ME, Iyer RB, Freedman RS. Cytokines, GM-CSF and IFNgamma administered by priming and post-chemotherapy cycling in recurrent ovarian cancer patients receiving carboplatin. J Transl Med. 2006;4:16-. Pubmedid: 16603073. Pmcid: PMC1457001.


• Apte SM, Bucana CD, Killion JJ, Gershenson DM, Fidler IJ. Expression of platelet-derived growth factor and activated receptor in clinical specimens of epithelial ovarian cancer and ovarian carcinoma cell lines. Gynecol Oncol. 2004 Apr;93(1):78-86. Pubmedid: 15047217.


• Apte SM, Fan D, Killion JJ, Fidler IJ. Targeting the platelet-derived growth factor receptor in antivascular therapy for human ovarian carcinoma. Clin Cancer Res. 2004 Feb;10(3):897-908. Pubmedid: 14871965.


• Tedjarati S, Baker CH, Apte S, Huang S, Wolf JK, Killion JJ, Fidler IJ. Synergistic therapy of human ovarian carcinoma implanted orthotopically in nude mice by optimal biological dose of pegylated interferon alpha combined with paclitaxel. Clin Cancer Res. 2002 Jul;8(7):2413-2422. Pubmedid: 12114447.

Dr. Sachin Apte is a Gynecologic Oncologist in The Center for Women’s Oncology where he also serves as Clinical Director of Gynecologic Oncology.  As a third generation physician, Dr. Apte embraces the patient-centered approach of a Gynecologic Oncologist.  All aspects of a patient – medical, social, and psychologic – are considered prior to making a treatment plan.  Many of the patients he cares for have complex medical problems.  Moffitt’s multi-disciplinary, collaborative practice offers patients access to a wide range of specialists as a way to optimize, coordinate, and individualize treatment.